NxThera Announces Humana and Aetna Coverage of the Rezūm® System to Treat BPH
MAPLE GROVE, Minn., April 4, 2017 /PRNewswire/ -- NxThera, Inc., a medical device company pioneering the application of its convective radiofrequency thermal technology to treat endourological conditions, today announced the Humana and Aetna health care insurance plans have joined other major insurers to provide coverage of the Rezūm® System for the minimally invasive treatment of benign prostatic hyperplasia (BPH), or enlarged prostate. With this added coverage from two of the country's top health care insurance companies, Rezūm is now available to more than 80 percent of men suffering from BPH across the country. Approximately 50 percent of men over the age of 50 and up to 90 percent of men over 80 suffer from BPH.
"Our mission is to improve the lives of men suffering from BPH, and the Rezūm System provides urologists and their patients with a safe, effective and durable treatment option with minimal discomfort," said Bob Paulson, president and CEO of NxThera. "The recently published 2-year data from our Rezūm II pivotal study demonstrates sustained and durable symptom relief and preserved sexual function in patients who were treated with the Rezūm System. These compelling clinical outcomes from a minimally invasive procedure that can be performed in an office or outpatient setting, provide an efficient and cost-effective BPH treatment option for urologists, patients and health plans."
The Rezūm System uses radiofrequency current to create thermal energy that is convectively delivered to obstructive prostate tissue through targeted, precise treatments with minimal discomfort. The thermal energy rapidly and effectively ablates the tissue that causes BPH, which is resorbed by the body's immune system to alleviate the symptoms of BPH and improve patients' quality of life and ability to urinate.
About NxThera
NxThera pioneered its convective radiofrequency thermal therapy platform technology to treat a variety of endourological conditions, beginning with BPH. The company is furthering the application of the technology platform through advanced research and development targeting the treatment of prostate cancer and kidney cancer. NxThera's FDA-cleared Rezūm System is a next-generation transurethral needle ablation system indicated to treat symptoms of BPH using radiofrequency energy that is convectively delivered to obstructive prostate tissue in targeted, precise thermal energy treatments, with minimal discomfort. Rezūm treatments provide improvements in BPH symptoms, urine flow and quality of life. Founded in 2008, NxThera is located in Maple Grove, Minn. For more information, visit www.Rezūm.com.
SOURCE NxThera
Share this article